Ibrutinib
- PDF / 170,150 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 103 Downloads / 174 Views
1
S
Various toxicities: 5 case reports In a single center, retrospective study of 58 patients, conducted between 04 August 2014 and 28 January 2019, five patients [ages and sexes not stated] were described, who developed Pneumocystis jiroveci pneumonia, acute respiratory distress syndrome (ARDS), atrial fibrillation (AF), severe pneumonia, sepsis, peritonitis and erysipelas during treatment with ibrutinib for chronic lymphocytic leukaemia (CLL). The patients, who had CLL, received treatment with ibrutinib [routes and dosages not stated]. The patients also received prophylactic treatment with valaciclovir and cotrimoxazole [trimethoprim/sulphamethoxazole] for herpetic infection reactivation and Pneumocystis jirovesi Pneumonia (PJP), respectively. Subsequently, the patients developed ibrutinib-related adverse reactions including grade 4 severe atypical PJP leading to ARDS and AF (one patient), grade 4 severe pneumonia leading to death due to sepsis (one patient), grade 3 peritonitis (one patient), grade 3 erysipelas (one patient) and AF (one patient). The patient, who developed AF, continued receiving ibrutinib 280 mg/day along with fondaparinux sodium [fondaparinux] prophylaxis for AF [duration of treatments to reactions onsets not stated; not all outcomes stated]. Author comment: "In our series, patients were systematically receiving prophylaxis for herpetic infection reactivation and for PJP, because even with [ibrutinib] treatment severe opportunistic infections may occur." "However, the most common toxicity leading to [ibrutinib] discontinuation in our series remains [atrial fibrillation]" Dimou M, et al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leukemia and Lymphoma 60: 2939-2945, No. 12, 15 Oct 2019. Available from: URL: http://doi.org/10.1080/10428194.2019.1620944 803442950 Greece
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
